What Is Cartesian Therapeutics, Inc. (RNAC) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cartesian Therapeutics, Inc.'s intrinsic value is estimated at $5.78. Trading at its current price of $8.68, the valuation engine raises significant caution: 6 of 7 models flag downside risk, projecting an average implied return of -33.4%. Notably, PWERM sees the most upside at +58.0% (fair value: $13.71), while ML-RIV is the most conservative at -78.4% ($1.88). The spread between these extremes — +136.4% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About RNAC?
7 of 13 models are currently active for RNAC. Of these, 1 model suggests upside while 6 models suggest overvaluation. The Bayesian DCF estimates RNAC's intrinsic value at $5.09, implying -41.4% downside from the current price. See which stocks rank higher →
How Does RNAC Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RNAC ranks #167 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Cartesian Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is RNAC a Value Trap?
CirclFi's Value Trap algorithm assigns RNAC a score of 11/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Cartesian Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Cartesian Therapeutics, Inc. scores 5.4 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +136.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RNAC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RNAC's 7 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad